NCT04231760View on ClinicalTrials.gov

The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

February 1, 2027

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Inhaled Nitric Oxide

Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.

DRUG

Placebo

Inhaled placebo, which consists of breathing medical grade air (21% O2).

All Listed Sponsors
lead

University of Alberta

OTHER

NCT04231760 - The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD | Biotech Hunter | Biotech Hunter